AIM The present study was designed to investigate the activity of two glibenclamide derivatives on glucose concentration. An additional aim was to identify the biodistribution of glibenclamide derivatives in different organs in a diabetic animal model. METHODS The effects of two glibenclamide derivatives on glucose concentration were evaluated in a diabetic animal model. In addition, glibencl...

Diabetes mellitus is associated with deterioration of glycemic control and progressive metabolic derangements. This study investigated the effect of honey as an adjunct to glibenclamide or metformin on glycemic control in streptozotocin-induced diabetic rats. Diabetes was induced in rats by streptozotocin. The diabetic rats were randomized into six groups and administered distilled water, honey...

Diabetes in subjects with hepatocyte nuclear factor (HNF)-1 gene mutations (maturity-onset diabetes of the young [MODY]-3) is characterized by impaired insulin secretion. Surprisingly, MODY3 patients exhibit hypersensitivity to the hypoglycemic actions of sulfonylurea therapy. To study the pharmacogenetic mechanism(s), we have investigated glibenclamide-induced insulin secretion, glibenclamide ...

Activating mutations in the Kir6.2 (KCNJ11) subunit of the ATP-sensitive potassium channel cause neonatal diabetes (ND). Patients with severe mutations also suffer from neurological complications. Glibenclamide blocks the open KATP channels and is the treatment of choice for ND. However, although glibenclamide successfully restores normoglycaemia, it has a far more limited effect on the neurolo...

Sulfonylureas, widely used as hypoglycemic agents in adults with type 2 diabetes, have neuroprotective effects preclinical models of central nervous system injury, and children neuropsychomotor impairments linked to neonatal diabetes secondary ATP-sensitive potassium channel mutations. In the human rodent retina, we show that glibenclamide-activated sulfonylurea receptor 1 (SUR1) is expressed r...

1 Glibenclamide is a widely used sulphonylurea for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). This agent has been reported to inhibit the activities of various ion channels and transporters. In the present study, we examined the effects of glibenclamide on the function of the H+/peptide cotransporters PEPT1 and PEPT2 by using stable transfectants. 2 Uptake of [14C]-glycyl...

The major risk factor for melioidosis, an infectious disease caused by B. pseudomallei, is diabetes mellitus. More than half of diabetic melioidosis patients in Thailand were prescribed glibenclamide. Recent evidence demonstrates that glibenclamide reduces pro-inflammatory cytokine production by polymorphonuclear neutrophils (PMNs) of diabetic individuals in response to this bacterial infection...

objectives we aim to evaluate the role of glibenclamide on the short-term outcome of patients with dai due to moderate to severe tbi. patients and methods in this controlled randomized clinical trial, 40 patients with moderate to severe tbi were assigned to glibenclamide (n = 20) and control (n = 20) groups. six hours after admission the intervention group received 1.25 mg glibenclamide every 1...

OBJECTIVES Glibenclamide was found to act as both a selective ATP-sensitive K(+) channel blocker and a vasorelaxant. The exact mechanisms underlying the relaxant effect of glibenclamide are unknown. The present study was designed to examine the role of endothelium/nitric oxide in glibenclamide-induced relaxation in rat isolated aortic rings. METHODS A combination of experimental approaches in...

The study was intended to find out the pharmacokinetic and pharmacodynamic drug interaction of eprosartan, a protype drug used to treat diabetic nephropathy with glibenclamide in healthy Albino Wistar rats following single and multiple dosage treatment. Therapeutic doses (TD) of glibenclamide, TD of eprosartan were administered to the animals. The blood glucose levels were estimated by GOD/POD ...